You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,030,457


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,030,457
Title:Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
Inventor(s): Jackson; Simon Mark (San Carlos, CA), Shan; Bei (Redwood City, CA), Shen; Wenyan (Wayne, PA), King; Chadwick Terence (North Vancouver, CA)
Assignee: Amgen, Inc. (Thousand Oaks, CA)
Application Number:12/197,093
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,030,457
Patent Claims:1. An isolated neutralizing antigen binding protein that binds to a PCSK9 protein comprising the amino acid sequence of SEQ ID NO: 1, wherein the neutralizing antigen binding protein comprises: a heavy chain polypeptide comprising the following complementarity determining regions (CDRs): a heavy chain CDR1 that is a CDR1 in SEQ ID NO: 49; a heavy chain CDR2 that is a CDR2 in SEQ ID NO: 49; a heavy chain CDR3 that is a CDR3 in SEQ ID NO: 49 and a light chain polypeptide comprising the following CDRs: a light chain CDR1 that is a CDR1 in SEQ ID NO: 23; a light chain CDR2 that a CDR2 in SEQ ID NO: 23; and a light chain CDR3 that is a CDR3 in SEQ ID NO: 23.

2. The isolated neutralizing antigen binding protein of claim 1, wherein the antigen binding protein is a LDLR competitive neutralizing antigen binding protein.

3. A pharmaceutical composition comprising at least one antigen binding protein according to claim 1, and a pharmaceutically acceptable excipient.

4. The isolated neutralizing antigen binding protein of claim 1, wherein the heavy chain polypeptide comprises all three of the following amino acid sequences: SEQ ID NO: 308, SEQ IDNO: 175, and SEQ ID NO: 180.

5. The isolated neutralizing antigen binding protein of claim 1, wherein the heavy chain polypeptide comprises all three of the following amino acid sequences: SEQ ID NO: 368, SEQ ID NO: 175, and SEQ ID NO: 180.

6. The isolated neutralizing antigen binding protein of claim 1, wherein the light chain polypeptide comprises all three of the following amino acid sequences: SEQ ID NO: 158, SEQ ID NO: 162, and SEQ ID NO: 395.

7. The isolated neutralizing antigen binding protein of claim 6, wherein the heavy chain polypeptide comprises all three of the following amino acid sequences: SEQ ID NO: 308, SEQ ID NO: 175, and SEQ ID NO: 180.

8. The isolated neutralizing antigen binding protein of claim 6, wherein the heavy chain polypeptide comprises all three of the following amino acid sequences: SEQ ID NO: 368, SEQ ID NO: 175, and SEQ ID NO: 180.

9. The isolated neutralizing antigen binding protein of claim 1, wherein the light chain polypeptide comprises: a CDR1 comprising SEQ ID NO: 158, a CDR2 comprising SEQ ID NO: 162, and a CDR3 comprising SEQ ID NO: 395.

10. The isolated neutralizing antigen binding protein of claim 1, wherein the heavy chain polypeptide comprises: a CDR1 comprising SEQ ID NO: 308, a CDR2 comprising SEQ ID NO: 175, and a CDR3 comprising SEQ ID NO: 180.

11. The isolated neutralizing antigen binding protein of claim 1, wherein the heavy chain polypeptide comprises: a CDR1 comprising SEQ ID NO: 368, a CDR2 comprising SEQ ID NO: 175, and a CDR3 comprising SEQ ID NO: 180.

12. The isolated neutralizing antigen binding protein of claim 10, wherein the light chain polypeptide comprises: a CDR1 comprising SEQ ID NO: 158, a CDR2 comprising SEQ ID NO: 162, and a CDR3 comprising SEQ ID NO: 395.

13. The isolated neutralizing antigen binding protein of claim 11, wherein the light chain polypeptide comprises: a CDR1 comprising SEQ ID NO: 158, a CDR2 comprising SEQ ID NO: 162, and a CDR3 comprising SEQ ID NO: 395.

14. The isolated neutralizing antigen binding protein of claim 1, wherein the heavy chain polypeptide comprises SEQ ID NO: 49 and the light chain polypeptide comprises SEQ ID NO: 23.

15. The isolated neutralizing antigen binding protein of claim 1, wherein each CDR is defined in accordance with the Kabat definition, the Chothia definition, the combination of the Kabat definition and the Chothia definition, the AbM definition, or the contact definition of CDR.

16. The isolated neutralizing antigen binding protein of claim 15, wherein each CDR is defined in accordance with the CDR definition of Kabat.

17. The isolated neutralizing antigen binding protein of claim 15, wherein each CDR is defined in accordance with the CDR definition of Chothia.

18. The isolated neutralizing antigen binding protein of claim 15, wherein each CDR is defined in accordance with the combination of the Kabat definition and the Chothia definition.

19. An isolated neutralizing human monoclonal antibody that binds to a PCSK9 protein comprising: a heavy chain polypeptide comprising the following complementarity determining regions (CDRs): a heavy chain CDR1 that is a CDR1 in SEQ ID NO: 49; a heavy chain CDR2 that is a CDR2 in SEQ ID NO: 49; a heavy chain CDR3 that is a CDR3 in SEQ ID NO: 49; and a light chain polypeptide comprising the following CDRs: a light chain CDR1 that is a CDR1 in SEQ ID NO: 23; a light chain CDR2 that a CDR2 in SEQ ID NO: 23; and a light chain CDR3 that is a CDR3 in SEQ ID NO: 23, wherein each CDR is defined in accordance with the CDR definition of Kabat.

20. The isolated neutralizing human monoclonal antibody of claim 19, wherein the heavy chain polypeptide comprises all three of the following amino acid sequences: SEQ ID NO: 308, SEQ ID NO: 175, and SEQ ID NO: 180.

21. The isolated neutralizing human monoclonal antibody of claim 19, wherein the heavy chain polypeptide comprises all three of the following amino acid sequences: SEQ ID NO: 368, SEQ ID NO: 175, and SEQ ID NO: 180.

22. The isolated neutralizing human monoclonal antibody of claim 20, wherein the light chain polypeptide comprises all three of the following sequences: SEQ ID NO: 158, SEQ ID NO: 162, and SEQ ID NO: 395.

23. The isolated neutralizing human monoclonal antibody of claim 21, wherein the light chain polypeptide comprises all three of the following sequences: SEQ ID NO: 158, SEQ ID NO: 162, and SEQ ID NO: 395.

24. The isolated neutralizing human monoclonal antibody of claim 19, wherein the heavy chain polypeptide comprises SEQ ID NO: 49 and the light chain polypeptide comprises SEQ ID NO: 23.

25. An isolated neutralizing human monoclonal antibody that binds to a PCSK9 protein comprising: a heavy chain polypeptide comprising: the amino acid sequence of SEQ ID NO: 180; the amino acid sequence of SEQ ID NO: 175; and the amino acid sequence of SEQ ID NO: 308; and a light chain polypeptide comprising: the amino acid sequence of SEQ ID NO: 395; the amino acid sequence of SEQ ID NO: 162; and the amino acid sequence of SEQ ID NO: 158.

26. An isolated neutralizing human monoclonal antibody that binds to a PCSK9 protein comprising: a heavy chain polypeptide comprising the following complementarity determining regions (CDRs): a heavy chain CDR1 that is a CDR1 in SEQ ID NO: 308 or a CDR1 in SEQ ID NO:368; a heavy chain CDR2 that is a CDR2 in SEQ ID NO: 175; a heavy chain CDR3 that is a CDR3 in SEQ ID NO: 180; and a light chain polypeptide comprising the following CDRs: a light chain CDR1 that is a CDR1 in SEQ ID NO: 158; a light chain CDR2 that is a CDR2 in SEQ ID NO: 162; and a light chain CDR3 that is a CDR3 in SEQ ID NO: 395.

27. An isolated neutralizing human monoclonal antibody that binds to a PCSK9 protein comprising: a heavy chain polypeptide comprising the following complementarity determining regions (CDRs): a heavy chain CDR1 that is a CDR1in SEQ ID NO: 49; a heavy chain CDR2 that is a CDR2 in SEQ ID NO: 49; a heavy chain CDR3 that is a CDR3 in SEQ ID NO: 49, wherein the heavy chain polypeptide comprises: the amino acid sequence of SEQ ID NO: 180; the amino acid sequence of SEQ ID NO: 175; and the amino acid sequence of SEQ ID NO: 308; and a light chain polypeptide comprising the following CDRs: a light chain CDR1 that is a CDR1 in SEQ ID NO: 23; a light chain CDR2 that a CDR2 in SEQ ID NO: 23; and a light chain CDR3 that is a CDR3 in SEQ ID NO: 23, wherein the light chain polypeptide comprises: the amino acid sequence of SEQ ID NO: 395; the amino acid sequence of SEQ ID NO: 162; and the amino acid sequence of SEQ ID NO: 158.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.